Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis
Conditions
Interventions
LT-02
Placebo
+1 more
Locations
1
Germany
Agaplesion Markus-Krankenhaus
Frankfurt a.M., Germany
Start Date
October 1, 2014
Primary Completion Date
October 5, 2018
Completion Date
October 5, 2018
Last Updated
January 27, 2020
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Dr. Falk Pharma GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions